中国重度抑郁症患者听觉诱发电位的响度依赖性及对抗抑郁药的反应
Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression.
作者信息
Lee Tien-Wen, Yu Younger W Y, Chen Tai-Jui, Tsai Shih-Jen
机构信息
Department of Psychiatry, Tzu Chi General Hospital, Hualien City.
出版信息
J Psychiatry Neurosci. 2005 May;30(3):202-5.
Abstract
OBJECTIVE
To investigate the loudness dependence of the auditory evoked potential (LDAEP) in predicting response to treatment for major depression.
METHODS
One hundred patients of Chinese ethnicity with major depression were divided into 2 groups, having strong or weak pretreatment LDAEP; the cutoff was the median of the LDAEP slope (for amplitude as a function of intensity). There were no between-group differences before treatment in terms of score on the Hamilton Depression Rating Scale (HDRS), age or sex distribution. The LDAEP for 4 intensity levels (60, 70, 80 and 90 dB) was recorded before treatment. Each patient then received fluoxetine 20 mg per day for 4 weeks. The response to treatment was evaluated by means of the HDRS.
RESULTS
At week 4, the HDRS score had declined by 44.3; for the group with strong LDAEP and by 34.4% for the group with weak LDAEP (t for mean difference = 2.584, p = 0.011).
CONCLUSION
Strong pretreatment LDAEP predicted a favourable response to treatment with a selective serotonin reuptake inhibitor in patients with major depression.
摘要
目的
研究听觉诱发电位响度依赖性（LDAEP）在预测重度抑郁症治疗反应中的作用。
方法
将100名中国汉族重度抑郁症患者分为两组，预处理LDAEP强组和弱组；以LDAEP斜率（振幅作为强度函数）的中位数为界值。治疗前两组在汉密尔顿抑郁量表（HDRS）评分、年龄或性别分布方面无组间差异。治疗前记录4个强度水平（60、70、80和90分贝）的LDAEP。然后，每位患者每天服用20毫克氟西汀，持续4周。通过HDRS评估治疗反应。
结果
在第4周时，HDRS评分下降了44.3；LDAEP强组下降了34.4%（平均差异的t值=2.584，p=0.011）。
结论
预处理LDAEP强可预测重度抑郁症患者对选择性5-羟色胺再摄取抑制剂治疗的良好反应。
相似文献
1
Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression.
J Psychiatry Neurosci. 2005 May;30(3):202-5.
2
Clinical symptoms of major depression are associated with the intensity dependence of auditory event-related potential components.
Psychiatry Res. 2009 Sep 30;169(2):139-43. doi: 10.1016/j.psychres.2008.06.009. Epub 2009 Aug 22.
3
The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depression.
Neurosci Lett. 2004 Sep 9;367(3):375-8. doi: 10.1016/j.neulet.2004.06.038.
4
A study of intensity dependence of the auditory evoked potential (IDAEP) in medicated melancholic and non-melancholic depression.
J Affect Disord. 2009 Oct;117(3):212-6. doi: 10.1016/j.jad.2009.01.009. Epub 2009 Feb 7.
5
The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression.
Pharmacopsychiatry. 2005 May;38(3):139-43. doi: 10.1055/s-2005-864126.
6
The loudness dependence of the auditory evoked potential (LDAEP) in schizophrenia, bipolar disorder, major depressive disorder, anxiety disorder, and healthy controls.
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Mar 17;34(2):313-6. doi: 10.1016/j.pnpbp.2009.12.004. Epub 2009 Dec 11.
7
Prediction of treatment response in major depression: integration of concepts.
J Affect Disord. 2007 Mar;98(3):215-25. doi: 10.1016/j.jad.2006.07.021. Epub 2006 Sep 20.
8
Response prediction to antidepressants using scalp and source-localized loudness dependence of auditory evoked potential (LDAEP) slopes.
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 1;44:100-7. doi: 10.1016/j.pnpbp.2013.01.012. Epub 2013 Jan 27.
9
Clinical characteristics associated with different strengths of loudness dependence of auditory evoked potentials (LDAEP) in major depressive disorder.
Psychiatry Res. 2012 Dec 30;200(2-3):374-81. doi: 10.1016/j.psychres.2012.06.038. Epub 2012 Sep 25.
10
Clinical implications of loudness dependence of auditory evoked potentials in patients with atypical depression.
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:7-12. doi: 10.1016/j.pnpbp.2014.05.010. Epub 2014 May 24.
引用本文的文献
1
Association between the loudness dependence of auditory evoked potentials and age in patients with schizophrenia and depression.
J Int Med Res. 2022 Jul;50(7):3000605221109789. doi: 10.1177/03000605221109789.
2
Intensity-Dependence of Auditory Evoked Potentials (IDAP) as a Neurophysiological Parameter to Predict Anti-Aggressive Responsiveness to SSRI Treatment.
Front Pharmacol. 2021 Aug 12;12:716338. doi: 10.3389/fphar.2021.716338. eCollection 2021.
3
Does the Loudness Dependence of Auditory Evoked Potential Predict Response to Selective Serotonin Reuptake Inhibitors?: A Meta-analysis.
Clin Psychopharmacol Neurosci. 2021 May 31;19(2):254-261. doi: 10.9758/cpn.2021.19.2.254.
4
Event-Related Potentials to Changes in Sound Intensity Demonstrate Alterations in Brain Function Related to Depression and Aging.
Front Hum Neurosci. 2020 Mar 27;14:98. doi: 10.3389/fnhum.2020.00098. eCollection 2020.
5
The Hypothesis on the Prediction of Treatment Response with Buspirone Augmentation along with Serotonergic Antidepressant in Patients with Major Depressive Disorder Using Loudness Dependence of Auditory Evoked Potentials: Two Cases and Review of the Literature for Evidence.
Psychiatry Investig. 2020 Mar;17(3):222-224. doi: 10.30773/pi.2019.0293. Epub 2020 Mar 11.
6
Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.
Drugs. 2017 Dec;77(18):1967-1986. doi: 10.1007/s40265-017-0819-9.
7
Demonstrating test-retest reliability of electrophysiological measures for healthy adults in a multisite study of biomarkers of antidepressant treatment response.
Psychophysiology. 2017 Jan;54(1):34-50. doi: 10.1111/psyp.12758.
8
Tobacco use is associated with reduced amplitude and intensity dependence of the cortical auditory evoked N1-P2 component.
Psychopharmacology (Berl). 2016 Jun;233(11):2173-2183. doi: 10.1007/s00213-016-4268-z. Epub 2016 Mar 17.
9
Prediction of long-term treatment response to selective serotonin reuptake inhibitors (SSRIs) using scalp and source loudness dependence of auditory evoked potentials (LDAEP) analysis in patients with major depressive disorder.
Int J Mol Sci. 2015 Mar 18;16(3):6251-65. doi: 10.3390/ijms16036251.
10
Cortical response variation with different sound pressure levels: a combined event-related potentials and FMRI study.
PLoS One. 2014 Oct 3;9(10):e109216. doi: 10.1371/journal.pone.0109216. eCollection 2014.
本文引用的文献
1
A rating scale for depression.
J Neurol Neurosurg Psychiatry. 1960 Feb;23(1):56-62. doi: 10.1136/jnnp.23.1.56.
2
Allelic variants of the functional promoter polymorphism of the human serotonin transporter gene is associated with auditory cortical stimulus processing.
Neuropsychopharmacology. 2003 Mar;28(3):530-2. doi: 10.1038/sj.npp.1300042. Epub 2002 Jul 25.
3
Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders.
Mol Psychiatry. 2002;7(10):1115-9. doi: 10.1038/sj.mp.4001141.
4
Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors.
Am J Pharmacogenomics. 2001;1(3):153-64. doi: 10.2165/00129785-200101030-00001.
5
Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists?
J Affect Disord. 2001 Jan;62(1-2):93-100. doi: 10.1016/s0165-0327(00)00353-0.
6
Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression.
Neuropsychopharmacology. 2000 Nov;23(5):587-90. doi: 10.1016/S0893-133X(00)00132-9.
7
The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression.
Psychopharmacology (Berl). 2000 Mar;148(4):404-11. doi: 10.1007/s002130050070.
8
A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide.
Arch Gen Psychiatry. 2000 Aug;57(8):729-38. doi: 10.1001/archpsyc.57.8.729.
9
Loudness dependence of auditory evoked potentials in obsessive-compulsive disorder: a pilot study.
Psychiatry Res. 2000 Apr 10;93(3):209-16. doi: 10.1016/s0165-1781(00)00106-2.
10
Management of nonresponse and intolerance: switching strategies.
J Clin Psychiatry. 2000;61 Suppl 2:10-2.
Zotero 插件